Navigation Links
O2h Continues to Support Senexis to Support Patent Filing Senexis Limited
Date:6/14/2010

CAMBRIDGE, England, June 14, 2010 /PRNewswire/ -- Executives from Senexis Limited (Cambridge,UK) signed an agreement with O2h (Ahmedabad, India) under which O2h will provide Senexis with chemistry services to support a patent filing on a novel chemical series that have shown potential in pre-clinical models, as disease modifying treatments for Alzheimer's Disease.

Dr. Mark Treherne, CEO of Senexis said that he appreciated O2h's continual support over the last 4 years in being a reliable chemistry partner, providing flexible multi-FTE chemistry support to the company.

Dr David Scopes, CSO at Senexis said "We have had a long collaboration with O2h and are happy that it is supporting us to further our programs into the important stage of patent applications. Senexis is again leveraging O2h's expertise on the synthetic chemistry methodology underpinning our lead compounds."

Sunil Shah, CEO, O2h "We have an incredibly good relationship and I was very happy learn about the positive Senexis data from their pre-clinical studies which allowed the Wellcome Trust to continue supporting this programme."

About Oxygen Healthcare Ltd

O2h is a 5 year old discovery services company co-located in Cambridge, UK and Ahmedabad, India. The Indian operations provide a high level of chemistry expertise while UK office provides project management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME. Further information on O2h can be found at http://www.o2h.com.

About Senexis Limited

Senexis is a drug discovery and development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of Alzheimer's disease and Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Senexis is now actively seeking development partners and further information on Senexis can be found at http://www.senexis.com.

    Contact information:
    Ekta Ahuja PhD
    info@o2h.com
    OXYGEN HEALTHCARE LTD
    23 Cambridge Science Park
    CB4 0EY

    Contact:
    SENEXIS LIMITED
    Babraham Research Campus
    Babraham, Cambridge, UK
    CB22 3AT


'/>"/>
SOURCE Oxygen Healthcare Ltd (O2h)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
2. NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
3. Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
4. US Oncology Continues to Set the Standard as a VAWD(CM) Accredited Wholesale Distributor
5. Igen Networks Corp continues to build a world class advisory board
6. Indiana Continues to Make Its Mark as a Leading Life Sciences Center
7. Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor
8. The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs
9. TechCFO Continues Research Triangle Park Expansion; Garrison Named New Partner
10. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
11. Health Robotics Continues its Global Expansion With December 09 ASHPs Launch of Joint Venture in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs of ... Assay from Salimetrics’ SalivaLab , the relationship between insulin and other relevant ...
Breaking Biology Technology:
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):